<DOC>
	<DOCNO>NCT01155713</DOCNO>
	<brief_summary>This study evaluate relative bioavailability 2 oral formulation TKI258 , effect food bioavailability TKI258 , adult patient advance solid tumor .</brief_summary>
	<brief_title>Bioavailability Food Effect Study TKI258 ( CSF Capsule vs. FMI Tablet ) Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Patients advance solid tumor progress despite standard therapy , standard therapy exist World Health Organization ( WHO ) performance status â‰¤ 2 Patient must meet protocolspecified laboratory value Patients brain cancer Patients concurrent severe and/or uncontrolled medical condition could compromise participation study Patients recover previous anticancer therapy Female patient pregnant , breast feeding , willing use effective method birth control Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Neoplasms</keyword>
	<keyword>Cancer</keyword>
	<keyword>Tumors</keyword>
	<keyword>Administration , oral</keyword>
	<keyword>Capsules</keyword>
	<keyword>CHIR258 , CHIR-258 , CHIR 258 , TKI258 , TKI-258 , TKI 258 ,</keyword>
	<keyword>Bioavailability ,</keyword>
	<keyword>Food</keyword>
</DOC>